PATENT CLAIM ANALYSIS

Application Number: 15925157
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210180"]

Abstract:
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Claim (Index 10):
The compound of  claim 8 , wherein R 6  is selected from the group consisting of piperidinyl, pyrrolidinyl, azepanyl, 7-azaspiro[3.5]nonanyl, and 2-azaspiro[3.3]heptanyl, all optionally substituted with 1-2 R 36 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.45902
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15833917', '15884112', '15499013', '15498990', '13953647']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8632271126068564
- 35 USC 102 Novelty (BERT): 0.5912223057473618
- Combined Prediction Score: 0.836026631920907
- Mean Citation Score: 493.91845
- Max Citation Score: 535.2776
- Similarity Product: 447.15478713784216

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test